AUTHORS
Shlomo Elias, Arnon Nagler I, MD2, Maud Ngoya3, Jan Vydra4, Maija Itälä-Remes5, Fabio Ciceri6, Mi Kwon , MD, PhD7, Montserrat Rovira8, Yves Chalandon9, Raynier Devillier, PhD10, Matthias Eder11, Désirée Kunadt12, Renato Fanin13, Mieke WH Roeven, MD, PhD14, Matthias Stelljes15, Christof Scheid, MD16, Thomas Schroeder17, Maria Calbacho18, Anna Grassi, MD19, Omur Gokmen Sevindik, MD20, Alejandro Luna21, José Luis López Lorenzo22, Alexandros Spyridonidis23, Francesco Saraceni, MD24, Frédéric Baron25, Jaime Sanz, MD, PhD26, Eolia Brissot, MD, PhD27
AFFILIATIONS
1 Hebrew University Hadassah Medical Center, Jerusalem, Israel
2 Sheba Medical Center, Ramat Gan, Israel
3 EBMT Office, Paris, France
4 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
5 Turku University Hospital, Turku, Finland
6 IRCCS San Raffaele Hospital Scientific Institute, Milan, Italy
7 Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, Gregorio Marañón Health Research Institute, Madrid, Spain, Hospital General Universitario Gregorio Marañón, Madrid, Spain
8 Hospital Clínic Barcelona, Barcelona, Spain
9 Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
10 Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France
11 Hannover Medical School, Hannover, Germany
12 University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
13 Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
14 Radboud University Medical Center, Nijmegen, Netherlands
15 University Hospital Münster, Münster, Germany
16 University Hospital Cologne, Cologne, Germany
17 University Hospital Essen, Essen, Germany
18 Hospital Universitario 12 de Octubre, Madrid, Spain
19 ASST Papa Giovanni XXIII, Bergamo, Italy
20 Demiroglu Bilim University, Istanbul Florence Nightingale Hospital, Istanbul, Turkey
21 Hospital Universitario Ramón y Cajal, Madrid, Spain
22 Fundación Jiménez Díaz University Hospital, Madrid, Spain
23 Research Committee, University of Patras, Patras, Greece
24 Azienda Ospedali Riuniti di Ancona, Ancona, Italy
25 University of Liège, Liège, Belgium
26 Hospital Universitari i Politècnic La Fe; Department of Medicine, Universitat de València, Valencia, Spain
27 Sorbonne University, Hôpital Saint-Antoine, Paris, France
ABSTRACT
Background: Treosulfan is increasingly used as an alternative to busulfan for conditioning before allogeneic hematopoietic stem cell transplantation (allo-HCT) because of its favorable toxicity profile while preserving potent antileukemic activity. However, the widespread adoption of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has introduced a distinct transplant platform in which conditioning-related toxicity, immune reconstitution, and transplant outcomes may differ from those observed with conventional GVHD prophylaxis. Consequently, whether the relative efficacy and safety of busulfan- and treosulfan-based conditioning remain similar in the PTCy era is unclear. In addition, comparative data between busulfan- and treosulfan-based conditioning regimens of equivalent intensity are limited.
Methods: We performed a retrospective EBMT registry analysis of adults with acute myeloid leukemia (AML) undergoing first allo-HSCT between 2012 and 2024 in complete remission. Eligible patients received fludarabine combined with busulfan (Bu2Flu or Bu4Flu) or treosulfan (Treo10Flu or Treo14Flu) as the sole alkylating agent, together with PTCy-based GVHD prophylaxis. Patients receiving TBI, thiotepa-containing conditioning, or ex vivo T-cell depletion were excluded. Outcomes included overall survival (OS), progression-free survival (PFS), relapse incidence (RI), non-relapse mortality (NRM), and GVHD. Multivariable analyses adjusted for relevant baseline covariates.
Results: A total of 1,050 patients were included: 129 received FluBu2, 484 FluBu4, 334 FluTreo10, and 103 FluTreo14. Median follow-up was 2.1 years, although follow-up was shorter in the FluTreo10 cohort. Donor types included haploidentical (32.8%), matched unrelated (31.3%), mismatched unrelated (23.6%), and matched sibling donors (12.3%). Baseline characteristics differed with respect to recipient CMV serostatus, HCT-CI, donor type, and Karnofsky performance status. In the overall cohort, the 2-year overall survival (OS), progression-free survival (PFS), relapse incidence (RI), and non-relapse mortality (NRM) were 72%, 65%, 24%, and 11%, respectively. Compared with the FluBu2 reference group, both myeloablative conditioning regimens were associated with improved PFS and OS in multivariable analysis. FluTreo14 was associated with improved PFS (HR 0.44, 95% CI 0.23–0.85; P=0.01) and OS (HR 0.38, 95% CI 0.20–0.75; P=0.005). Similarly, FluBu4 was associated with improved PFS (HR 0.67, 95% CI 0.44–1.00; P=0.05) and OS (HR 0.59, 95% CI 0.39–0.91; P=0.02). FluTreo10 demonstrated a favorable but non-significant trend toward improved PFS (HR 0.71, 95% CI 0.44–1.14) and OS (HR 0.63, 95% CI 0.38–1.03). Relapse incidence, non-relapse mortality, and acute GVHD did not differ significantly between conditioning regimens. FluBu4 was associated with a lower risk of extensive chronic GVHD (HR 0.25, 95% CI 0.07–0.81; P=0.02).
Conclusions: In adult AML patients receiving PTCy-based GVHD prophylaxis, myeloablative conditioning was associated with the most favorable survival outcomes. Both busulfan- and treosulfan-based myeloablative conditioning regimens demonstrated favorable outcomes, suggesting that myeloablative conditioning can be successfully delivered with either alkylating agent in the setting of PTCy-based GVHD prophylaxis. Matched-intensity analyses comparing Bu2Flu with Treo10Flu and Bu4Flu with Treo14Flu are warranted to better define the relative efficacy and safety of busulfan- and treosulfan-based conditioning.
DISCLOSURES
Shlomo Elias: No relevant conflicts of interest to declare.